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Objectives To evaluate bone mineral density (BMD) in preterm neonates at discharge and identify the optimum
cutoff values for serum alkaline phosphatase (ALP) and phosphorus (P) concentrations to diagnose the severity of
metabolic bone disease of prematurity.
Study design A total of 336 preterm neonates (#31 weeks’ gestation and birth weight #1500 g) were prospec-
tively evaluated for BMD before discharge using dual-energy X-ray absorptiometry.
Results BMD reference values (at ALP #500 IU/L) were measured in 279 patients. BMD was classified as poor
(<10th percentile) at <0.068 g/cm2, fair (10th-25th percentile) at 0.068-0.081 g/cm2, good (25th-75th percentile)
at 0.081-0.112 g/cm2, and very good (>75th percentile) at >0.112 g/cm2. Increased BMD was associated with a
higher birth weight, short duration of parenteral nutrition, and the absence of small for gestational age status, patent
ductus arteriosus, intraventricular hemorrhage, and other clinical variables. Metabolic bone disease of prematurity
was absent (ALP#500 IU/L) in 279 cases (83.0%), mild (ALP >500 IU/L and P$4.5 mg/dL) in 46 cases (13.7%), and
severe (ALP >500 IU/L and P <4.5 mg/dL) in 11 cases (3.3%).
Conclusions A BMD >0.068 g/cm2 at discharge indicated a 90.3% probability of not developing metabolic bone
disease of prematurity. The factors independently associated with increased BMD included higher birth weight,
short duration of parenteral nutrition, absence of intraventricular hemorrhage, exclusive feeding of fortified breast
milk, and older age at discharge. (J Pediatr 2014;164:499-504).
M
etabolic bone disease of prematurity is a new designation for osteopathy of prematurity that highlights the biochem-
ical andmetabolic aspects of the disorder, including the blood concentrations of alkaline phosphatase (ALP), calcium
(Ca), phosphorus (P), parathyroid hormone (PTH), and vitamin D.1Metabolic bone disease of prematurity occurs in
up to 23% of newborns weighing <1500 g at birth and in 55% of those weighing <1000 g who have not received fortified breast
milk or formula with high Ca and P content.2 The severity of the alterations of Ca-P metabolism in metabolic bone disease of
prematurity correlate with the degree of ALP elevation at age 1 month3 and with a decrease in serum P level and, in some cases,
Ca level. The expression of metabolic bone disease of prematurity in the bones is quantified by bone mineral density (BMD)
analysis.
Bone mineralization can be expressed as bone mineral content (based on grams of hydroxyapatite; rarely used), bone
mineral content per centimeter cubed, or BMD (the most widely used measurement). BMD is generally assessed by
dual-energy X-ray absorptiometry (DXA) scanning, which measures the Ca content in the bones, expressed as grams
of hydroxyapatite per centimeter squared. The exposure to ionizing radiation is minimal (effective dose, 0.001 mSv;
<0.1 mrem). The technique is precise and reproducible, and takes only 5 minutes. The trabecular bone is preferred,
and the lumbar region is generally used in neonates. Modern portable machines can analyze the forearm and the calca-
neus. BMD measurement is the method of choice for children, because the results are independent of anthropometric
variables and gestational age.4 Moreover, according to Yeste et al,5 there are no significant sex-based differences in
BMD.
Our aims in the present study were to evaluate BMD at discharge in preterm infants of#31 weeks’ gestation with birth weight
#1500 g, and to identify the optimum cutoff values for serum ALP and P concentrations to diagnose and grade metabolic bone
disease of prematurity. We also analyzed the factors influencing BMD.From the 1Neonatal Service and 2Nuclear Medicine
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ALP Alkaline phosphatase
BMD Bone mineral density
BPD Bronchopulmonary dysplasia
Ca Calcium
DXA Dual-energy X-ray absorptiometry
P Phosphorus
PTH Parathyroid hormone
SGA Small for gestational age
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Table I. Demographic and clinical characteristics of the
study cohort (n = 336)
Characteristic Value
BMD, g/cm2, median (IQR) [range] 0.092 (0.078-0.111)
[0.01-0.36]
Birth weight, g, median (IQR) [range] 970 (821-1120)
[460-1500]
Gestational age, wk, median (IQR) [range] 28 (26-29)
[24 wk 1 d-31 wk 6 d]
SGA (<10th percentile), n (%) 75 (22.3)
Prenatal steroid use, n (%) 302 (92.4)
Male sex, n (%) 163 (48.5)
Respiratory distress syndrome, n (%) 174 (52.4)
Patent ductus arteriosus, n (%) 113 (33.6)
Surgical closure, n (%) 23 (7.1)
Intraventricular hemorrhage, n (%) 63 (19.0)
Cystic periventricular leukomalacia, n (%) 11 (3.3)
Necrotizing enterocolitis, n (%) 9 (2.7)
Cholestasis, n (%) 11 (3.3)
Early sepsis (hemoculture positive), n (%) 3 (0.9)
Late sepsis (hemoculture positive), n (%) 56 (16.9)
BPD (oxygen at 28 days of life), n (%) 28 (8.4)
Retinopathy of prematurity, n (%) 145 (43.7)
Degree 2-3, n (%) 68 (20.5)
Postmenstrual age at densitometry, wk,
median (IQR) [range]
36.1 (34.6-38.3)
[30-49]
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Preterm infants with a gestational age of #31 weeks and a
birth weight #1500 g who were admitted to our neonatal
unit between March 2002 and December 2011 and under-
went bone densitometry before discharge were included in
this analysis. Infants with malformations, chromosomal ab-
normalities, or metabolopathies, and those for whom
parental consent was not obtained, were excluded. The study
was approved by our institution’s Neonatology Ethics Com-
mittee.
Bone densitometry was measured by DXA (Lunar Prodigy;
GE Healthcare, Wauwatosa, Wisconsin) and processed using
enCore version 8.10.027 software (GE Healthcare). The re-
sults were based on the traversal of a low-dose radiograph
beamwith 2 different energy peaks through the lumbar spine.
One peak was absorbed primarily by the soft tissue, and the
other was absorbed by bone tissue. The amount of soft tissue
was subtracted from the total tissue, and the result was re-
corded as the BMD. Image acquisition was performed in
the lumbar spine in the “thin” mode (default setting).5,6
The BMD values of the L1-L4 vertebrae were measured,
and the average value of the L2-L4 segment was used for
the final quantification.
Serum Ca, P, and ALP levels and tubular P reabsorption
were determined at discharge, at approximately the same
time as bone densitometry was performed.
Following the standard practice for breastfed infants, the
mother’s milk was enriched using Enfamil Human Milk
Fortifier (Mead Johnson, Glenview, Illinois). A standard pre-
term formula (Alprem; Nestle, Vevey, Switzerland) was given
to the formula-fed infants.
The independent variables were year of birth; birth weight;
gestational age; small for gestational age (SGA) status; prena-
tal steroid use; sex; postmenstrual age at discharge; neonatal
complications, such as respiratory distress syndrome, patent
ductus arteriosus, intraventricular hemorrhage, periventric-
ular leukomalacia, necrotizing enterocolitis, cholestasis, late
hemoculture-positive sepsis, bronchopulmonary dysplasia
(BPD), and retinopathy of prematurity; treatments adminis-
tered, such as parenteral nutrition, diuretics, xanthines, feed-
ings, and mechanical ventilation; and serum Ca, P, and ALP
and tubular P reabsorption values. Year of birth was analyzed
because of the long duration of the study. SGA status was
defined as birth weight below the 10th percentile for gesta-
tional age and sex, based on the neonatal curves of Olsen
et al.7 BPD was defined as a requirement for supplemental
oxygen at 28 days of life. The dependent variables (or result)
were BMD (quantitative) and metabolic bone disease of pre-
maturity (categorical: 0, none; 1, mild; 2, severe).
The normal distribution of the quantitative variables was
analyzed using the Kolmogorov-Smirnov test before the
parametric tests. When the distribution was not normal or
a difference in variance (Snedecor F distribution) was
observed, nonparametric techniques were used. Parametric
variables were recorded as mean  SD; nonparametric vari-500ables, as median (IQR). The categories of the qualitative vari-
ables were abstracted as frequency and percentage. For the
quantitative variables, nonparametric comparisons were per-
formed using the Kruskal-Wallis test to compare more than
2 groups. Associations between qualitative variables were
analyzed using the c2 test with the “linear-by-linear associa-
tion” option when the categories were progressive. Correla-
tions were evaluated using the nonparametric Spearman
rho test. Quantitative variables and qualitative variables
with progressive categories were included. Linear regression
was used for the multivariate analysis, and the dependent
and independent variables were quantitative or qualitative
with progressive categories. A P value <.05 was considered
statistically significant.
Results
A total of 336 preterm infants who underwent biochemical
analyses and BMD assessment were included (Table I). The
distributions of all quantitative variables except weight
were abnormal, and thus nonparametric tests were always
applied.
The closest correlations between BMD and any other vari-
ables were seen for ALP (n = 333, rho =0.235; P < .001) and
P (n = 322; rho = 0.327; P < .001). A preliminary analysis
identified the best cutoff points for serum ALP and P levels
for categorizing the presence and severity of metabolic
bone disease of prematurity. After sorting the cases into
different groups that were theoretically related to metabolic
bone disease of prematurity (Table II), the classification
that showed the highest correlation with the BMD value
was selected. The concentration threshold of ALP to
indicate metabolic bone disease of prematurity was 500Figueras-Aloy et al
Table II. Ordinal correlations between BMD and metabolic bone disease of prematurity according to cutoff values for
serum ALP (300, 500, 700, and 900 IU/L) and P (4.5 and 5.5 mg/dL)
Correlation with BMD
Metabolic bone disease of prematurity category
rho; P valueNone Mild Moderate Severe
According to ALP ALP #300 ALP 301-700 ALP >700 0.169; .002
ALP #500 ALP 501-700 ALP >700 0.264; <.001
ALP #500 ALP 501-700 ALP 701-900 ALP >900 0.264; <.001
According to ALP and P (4 groups) ALP #300 ALP >300
P $5.5
ALP >300
P 4.5-5.5
ALP >300
P <4.5
0.238; <.001
ALP #500 ALP >500
P $5.5
ALP >500
P 4.5-5.5
ALP >500
P <4.5
0.272; <.001
ALP #700 ALP >700
P $5.5
ALP >700
P 4.5-5.5
ALP >700
P <4.5
0.098; .074
ALP #900 ALP >900
P $5.5
ALP >900
P 4.5-5.5
ALP >900
P <4.5
0.055; .319
According to ALP and P (3 groups) ALP #500 ALP >500
P $5.5
ALP >500
P <5.5
0.271; <.001
ALP #500 ALP >500
P $4.5
ALP >500
P <4.5
0.290; <.001
March 2014 ORIGINAL ARTICLESIU/L, because the absolute values of the ordinal correlations
with BMD were highest when using this cutoff point (0.264,
0.272, and 0.290; Table II). The maximum value of the
correlation (0.290) was obtained by associating the ALP
and P concentrations with a cutoff point of 4.5 mg/dL to
differentiate mild from severe metabolic bone disease of
prematurity. The classification included 3 groups: none
(ALP #500 IU/L), mild (ALP >500 IU/L and P $4.5 mg/
dL), and severe (ALP >500 IU/L and P <4.5 mg/dL). The
distribution of these categories in our cohort was 279 none
(83.0%), 46 mild (13.7%), and 11 severe (3.3%).
To determine the reference BMD values, 279 patients with
a serum ALP level #500 IU/L were evaluated. In these pa-
tients, the 5th, 10th, 25th, 50th, 75th, 90th, and 95th percen-
tiles were 0.059, 0.068, 0.081, 0.095, 0.112, 0.134, and 0.147 g/
cm2, respectively. Bone density was classified as poor (<10th
percentile), fair (10th-25th percentile), good (25th-75th
percentile), or very good (>75th percentile). Mean BMD
was lower in the 57 patients with ALP >500 IU/L compared
with those with ALP #500 IU/L (P < .001).
A good BMD was associated with higher birth weight;
absence of SGA; a short period of parenteral nutrition (which
implies increased enteral nutrition); absence of patent ductus
arteriosus, intraventricular hemorrhage, cholestasis, and late
sepsis; reduced need for mechanical ventilation; exclusive
feeding of fortified breast milk; and normal Ca-P metabolism
(high Ca, high P, and low ALP) (Table III).
On multivariate linear regression of 299 preterm infants,
BMD was independently associated with higher birth weight,
no history of intraventricular hemorrhage, a short period of
parenteral nutrition, exclusive feeding of fortified breast
milk, and older corrected postmenstrual age at discharge.
Only 1 of the 11 patients (9.1%) with severe metabolic
bone disease of prematurity had a BMD value above the
25th percentile, and only 27 of the 279 patients (9.7%)
without metabolic bone disease of prematurity had a BMD
value below the 10th percentile (Table IV). A BMD >0.068
g/cm2 (10th percentile) at discharge was associated with aMetabolic Bone Disease and Bone Mineral Density in Very Preter90.3% probability of not developing metabolic bone disease
of prematurity. As expected, BMD, ALP, P, and Ca values
differed significantly among the 3 groups (Table IV).
Discussion
None of the evaluated metabolites (Ca, P, ALP, PTH, and
vitamin D) alone can be considered a marker of metabolic
bone disease of prematurity.8 Serum Ca and P levels may
be normal despite reduced storage levels, because of the effect
of PTH.9 The most widely accepted marker of metabolic
bone disease of prematurity is ALP,10 but cutoff points for
defining osteopenia vary widely among studies, from 300
IU/L (the maximum normal level in newborns10) to 900
IU/L.11 According to Hung et al,3 an ALP level >700 IU/L
at 3 weeks postnatal age is predictive of osteopenia at term,
with a sensitivity of 73% and a specificity of 74%. In our
study, an ALP level of 500 IU/L was chosen as the threshold
value, similar to that reported by Harrison et al,1 because it
was associated with the best division of the total patient sam-
ple according to BMD.
Assessing BMD with entire body and spine studies is rec-
ommended. For the entire body results, it is suggested that
the value of the head not be taken into account because of
the different bone evolution of the head relative to the rest
of the skeleton. The software version available at the time of
this study was enCore version 8. We tested this software in
neonates and identified problems linked to cell size (4.8 
6.5 mm) and faster acquisition, which resulted in lower
spatial resolution. The software did not allow exclusion of
results for the head/cranium from the overall BMD results
or correction for the influence of immobilization devices
on the results. The resulting variability was decreased in
children weighing >15 kg. Thus, we decided to discontinue
the use of this software in newborn patients. The spinal
assessment allowed better bone edge recognition and reli-
able monitoring of the bone limits, and eliminated potential
artifacts.5,6m Infants 501
Table III. Factors influencing BMD
Factor
BMD category (n = 336)
P value*Poor (n = 46) Fair (n = 53) Good (n = 158) Very good (n = 79)
BMD, g/cm2, median (IQR) 0.059 (0.051-0.063) 0.076 (0.071-0.079) 0.094 (0.087-0.102) 0.127 (0.119-0.143) -
Year of birth, median (IQR) 2008 (2006-2010) 2009 (2007-2010) 2008 (2007-2010) 2009 (2007-2010) .027
Birth weight, g, median (IQR) 910 (770-1020) 840 (760-970) 990 (860-1125) 1070 (885-1200) .000
Gestational age, wk, median (IQR) 28 (26-29) 27 (26-29) 28 (27-29) 28 (27-29) .224
SGA <10th percentile, n (%) 15 (32.6) 16 (30.2) 22 (13.9) 8 (10.1) .000
Prenatal steroids, n (%) 40 (90.9) 48 (90.5) 143 (93.5) 71 (92.2) .912
Male sex, n (%) 28 (60.9) 30 (56.6) 68 (43.0) 37 (46.8) .103
Respiratory distress syndrome, n (%) 18 (43.8) 33 (68.8) 78 (54.2) 33 (49.3) .808
Patent ductus arteriosus, n *%) 20 (43.5) 18 (34.0) 57 (36.1) 18 (22.8) .031
Surgical closure, n (%) 4 (9.8) 7 (14.9) 11 (7.8) 1 (1.5) .067
Intraventricular hemorrhage, n (%) 12 (29.3) 14 (29.2) 23 (16.0) 10 (14.9) .016
Cystic periventricular leukomalacia, n (%) 1 (2.4) 0 8 (5.6) 2 (3.0) .452
Necrotizing enterocolitis, n (%) 2 (4.9) 2 (4.2) 1 (0.7) 1 (1.5) .102
Cholestasis, n (%) 3 (7.3) 5 (10.4) 1 (0.7) 1 (1.5) .007
Late sepsis hemoculture positive, n (%) 11 (26.8) 10 (20.8) 22 (15.3) 8 (11.9) .030
BPD, n (%) 6 (13.0) 7 (13.2) 10 (6.3) 5 (6.3) .237
Retinopathy of prematurity, n (%) 18 (43.9) 32 (66.7) 65 (45.1) 23 (34.3) .049
Degree 2-3, n (%) 9 (22.0) 16 (33.3) 27 (18.8) 10 (15.0) .093
Parenteral nutrition, d, median (IQR) 9 (8-13) 8 (7-10) 7 (6-9) 7 (5.5-9) .000
Diuretic use, d, median (IQR) 0 (0-0) 0 (0-2) 0 (0-2) 0 (0-2) .879
Xanthine use, d, median (IQR) 40 (24-65) 47 (33-60) 40 (23-52) 39 (26-52) .465
Breast milk with/without formula, n (%) 37 (80.4) 50 (94.3) 138 (87.3) 76 (96.2) .019
Exclusively fortified breast milk, n (%) 22 (47.8) 34 (64.2) 113 (71.5) 60 (75.9) .007
Mechanical ventilation, d, median (IQR) 1 (0-5) 2 (0-5) 0 (0-2) 0 (0-2) .012
Postmenstrual age at densitometry, wk, median (IQR) 37.2 (36.1-38.6) 36.4 (34.8-38.4) 35.7 (34.6-37.6) 35.4 (34.9-38.3) .031
Serum Ca, mg/dL, median (IQR) 9.5 (9.1-9.8) 9.8 (9.4-10.2) 9.8 (9.4-10.1) 9.9 (9.6-10.2) .004
Serum P, mg/dL, median (IQR) 6 (5-6.5) 6 (5.3-6.8) 6.6 (6.1-7.3) 6.9 (6.1-7.3) .000
Serum ALP, IU/L, median (IQR) 455 (320-568) 368 (275-504) 316 (255-391) 318 (259-414) .000
Tubular P reabsorption, %, median (IQR) 81 (66-92) 79 (69-90) 85 (75-91) 85 (76-89) .340
*c2 or Kruskal-Wallis test.
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dren5,12 and infants, particularly preterm infants.4,5,13,14
BMD is typically assessed in infants before discharge or dur-
ing the first month after discharge. Measurements of BMD at
discharge invariably reflect any effects of neonatal complica-
tions and the type of nutrition and treatments administered,
which reflects the actual clinical situation of these infants.
BMD is not associated with sex5,15 and increases with age.5
Rigo et al4 studied 80 preterm infants weighing <1500 g at
the time of discharge who were at appropriate weight for
gestational age and found a mean bone mineral content of
30.8 g and a bone area of 221 cm2, with a ratio of 0.139 g/
cm2. The mean DXA value measured in the lumbar regionTable IV. Characteristics by metabolic bone disease of prema
Characteristic
Metabolic bon
None
Densitometry, g/cm2, median (IQR) 0.094 (0.081-0.112)
BMD category, n (%)
Poor (<10th percentile) 27 (9.7)
Fair (10th-25th percentile) 39 (14.0)
Good (25th-75th percentile) 141 (50.5)
Very good (>75th percentile) 72 (25.8)
Serum ALP, IU/L, median (IQR) 314 (250-377)
Serum P, mg/dL, median (IQR) 6.7 (6.0-7.3)
Serum Ca, mg/dL, median (IQR) 9.8 (9.4-10.2)
*c2 or Kruskal-Wallis test.
502in our preterm population (0.09 g/cm2) was less than the
lowest value reported previously (0.14 g/cm2),4,13 and did
not reach the value reported for infants at near to term.16
This finding may be related to our infants’ shorter gestational
time (an average of 28.2 weeks vs 31.2 weeks13), lower birth
weight (average of 1001 g vs 1480 g13), and evaluation at a
younger corrected age (36 weeks, 1 month corrected age vs
0-1.5 months17), with less time for catch-up. Yeste et al13 re-
ported correlations between BMD at 0-1.5 months and gesta-
tional age (r = 0.63; P < .001) and birth weight (r = 0.31; P =
.02).
In our study, birth weight was the clinical variable with the
highest positive correlation with BMD at discharge. Rigoturity category
e disease of prematurity category
P value*Mild Severe
0.082 (0.065-0.093) 0.060 (0.059-0.071) <.001
<.001
13 (28.3) 6 (54.5)
10 (21.7) 4 (36.4)
16 (34.8) 1 (9.1)
7 (15.2) 0
568 (525-688) 568 (552-645) <.001
6.1 (5.6-6.6) 3.9 (3.65-4.15) <.001
9.6 (9.3-10.0) 9.4 (9.0-9.75) .020
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preterm neonates.14 These findings suggest that BMD is
conditioned primarily by prenatal mineralization. Mineral
accretion at the time of discharge is reportedly greater in pre-
term infants fed formula enriched with Ca and P.18,19 We did
not observe this effect, because our preterm infants received
fortified breast milk or formula designed for preterm infants.
The infants receiving fortified breast milk had higher BMD
values, and fortified breast milk feeding was a significant in-
dependent variable in our linear regression analysis. Fewtrell
et al20 reported that supplementation of breast milk in pre-
term infants was not associated with a higher bone mineral
content at age 20 years. Other variables, including gestational
age, protein content,21 and solubility of Ca and P salts, may
influence BMD. Breast milk Ca is absorbed at a rate of
70%, compared with 25%-30% for formula Ca. Lactose en-
courages absorption.22 Rigo et al4 reported the maximum
retention of Ca (91 mg/kg/day) and higher bone accretion
at discharge in 9 preterm infants who received breast milk
with a fortifier containing 170 mg/kg/day of highly soluble
Ca glycerophosphate. Rigo et al23 recommended adminis-
tering 100-160 mg/kg/day of highly bioavailable Ca salts
with 60-90 mg/kg/day of P and 800-1000 IU/day of vitamin
D. The European Society of Paediatric Gastroenterology,
Hepatology, and Nutrition’s Committee on Nutrition ad-
vises a Ca intake of 120-140 mg/kg/day.24 Our results also
suggest that SGA preterm infants have reduced BMD. Lapil-
lonne et al25 reported decreased BMD in 20 intrauterine
growth-restricted infants at term.
Generally, preterm infants recover from low BMD by age 2
years,13 or by 6-12 months with the use of enriched formula.4
Studies of patients aged 8-12 years have revealed delayed stat-
ure in children who have recovered from low BMD.4
Although metabolic bone disease of prematurity is a self-
limiting process, the benefits of rapid recovery include the
avoidance of fractures, a lower rate of dolichocephaly, and
improved growth26 in addition to long-term benefits, such
as increased bone mass20 and reduced osteopenia in adult-
hood.
In a preterm infant, the diagnosis of metabolic bone dis-
ease of prematurity (ALP >500 IU/L) or low BMD at
discharge (<0.068 g/cm2), or during hospitalization if ALP
and P are assessed periodically, justifies the application of
clinical interventions that may include provision of suffi-
cient Ca and P in parenteral nutrition (75 mg/kg/day of
Ca and 44 mg/kg/day of P)27 over the shortest period
possible; provision of sufficient Ca and P in enteral nutri-
tion2; fortification of breast milk or use of a specific formula
for preterm infants28; changing of furosemide to chlorothi-
azide as early as possible; reduction in the use of dexameth-
asone; administration of oral vitamin D at 400-800 IU/day;
physiotherapy to mobilize the upper and lower extremities
in stable preterm infants to promote bone mineralization29;
and careful management of preterm infants with severe
metabolic bone disease of prematurity to prevent fractures.
In addition, in our neonatal unit, infants with severe meta-
bolic bone disease of prematurity are treated with vitamin DMetabolic Bone Disease and Bone Mineral Density in Very Preter(800-1200 IU/day), Ca (100-150 mg/kg/day), and P (90 mg/
kg/day), with the highest doses given to those with a BMD
value <0.068 g/cm2.
A weakness of the present study is its long duration (almost
10 years). However, postnatal steroids were never used to
treat BPD for more than 5 days, and the same artificial for-
mula and human milk fortifier was used throughout the
study period. Birth year did not affect BMD in the multivar-
iate analysis. An additional weakness is the assumption that
all infants with a serum ALP level #500 IU/L have normal
bone density. Although this assumption may be reasonable
in clinical practice, BMD decreases in virtually all preterm in-
fants from birth to discharge,4,14 and serum ALP level ap-
pears to be of only limited value in predicting bone
mineralization in preterm infants.10 The closest correlations
seen in the present study were between BMD and ALP and
P levels, and thus we decided to diagnose and grademetabolic
bone disease of prematurity based on the combined values.
Our results agree with those reported by Backstr€om et al,30
although we identified different cutoff values (ALP >500
IU/L vs 900 IU/L and P <4.5 mg/dL vs 5.5 mg/dL). n
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